Glaukos (GKOS)
(Delayed Data from NYSE)
$130.98 USD
+4.18 (3.30%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $130.94 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$130.98 USD
+4.18 (3.30%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $130.94 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Zacks News
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos (GKOS) Q3 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) third-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.
Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medical Device Stocks to Watch for Earnings on Nov 1: MCK & More
by Indrajit Bandyopadhyay
Medical Device companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, QDEL, GKOS and NARI are placed ahead of their earnings release.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Glaukos (GKOS) Q2 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) second-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.
Compared to Estimates, Glaukos (GKOS) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 3.51% and 7.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Medical Device Aug 2 Earnings Roster: MCK, FMS & GKOS
by Indrajit Bandyopadhyay
Medical Device players are expected to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MCK, FMS and GKOS are likely to have performed this time.
OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 0% and 1.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos' (GKOS) New Tie-Up to Address Chronic Eye Disease
by Zacks Equity Research
Glaukos' (GKOS) new partnership is expected to advance next-generation wearable patient engagement and diagnostic technology, thereby making the detection of eye diseases more efficient.
Glaukos (GKOS) Stock Hits 52-Week High: More Room to Grow?
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos' (GKOS) Q1 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
Glaukos' (GKOS) Q1 revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to wider operating loss.
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 3.28% and 10.38%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos' (GKOS) Q4 Earnings Beat Estimates, Sales Decline Y/Y
by Zacks Equity Research
Glaukos' (GKOS) Q4 revenues beat estimates but fall year over year. Lower revenues, along with higher expenses, hurt margins.
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 5.36% and 5.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Q4 Earnings on Feb 22: FMS, GKOS & More
by Debanjana Dey
MedTech companies' Q4 results are likely to reflect strength in customer demand. Let's see how FMS, GKOS, MMSI and DVA are placed ahead of their earnings releases.
Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Glaukos (GKOS) on the back of continued strength in its flagship iStent.
Glaukos (GKOS) Up 0.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.